May 3 |
Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here Why
|
Apr 19 |
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
|
Mar 31 |
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
|
Mar 29 |
AEON Biopharma Announces Redemption of Public Warrants
|
Mar 29 |
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 19 |
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
|
Mar 19 |
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
|
Dec 12 |
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
|
Nov 13 |
AEON Biopharma Reports Third Quarter 2023 Financial Results
|